Status:
COMPLETED
Improving Adherence to Smoking Cessation Medication Among PLWHA
Lead Sponsor:
NYU Langone Health
Conditions:
Tobacco Use Cessation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Smoking rates among individuals living with HIV/AIDS range between 47% and 65%, a prevalence that is roughly three times the rate of the general population. This elevated prevalence is alarming given ...
Detailed Description
To accomplish the study's aims the investigators propose a three phase study: PHASE 1) Formative phase (n=40) to pretest text messages and to explore barriers to cessation and adherence to cessation m...
Eligibility Criteria
Inclusion
- Current patient at one of two SLR CCC clinics with a designated physician (had intake visit and enrolled into clinic)
- Age 18 years or older;
- Current or regular smoker (\>5 cigarettes per day);
- Carbon Monoxide (CO) monitor reading of \>8 ppm;
- Willingness to set a quit date;
- Able to conduct activities in English;
- Ability to provide informed consent;
- Willingness to carry/use a cell phone; AND
- Eligible to take varenicline as determined by the patient's primary care provider
Exclusion
- Unstable cardiovascular disease (e.g. uncontrolled blood pressure, unstable angina, or myocardial infarction in the past 4 weeks);
- Current homicidal or suicidal ideation, history of suicidal ideation, or history of psychosis;
- Has a serious or untreated psychiatric illness (major depression, bipolar or schizophrenia);
- Severe renal impairment (defined as having a creatinine clearance \< 30mL/min);
- Currently using smokeless tobacco;
- Currently using FDA-approved smoking cessation medication or other smoking cessation treatment and or participating in another smoking cessation program;
- Active drug use identified by a score of 6 or above on DAST-10 Drug Abuse Screening Test;
- Alcohol dependence or risk drinking identified by a score of 5 or above for men and 4 or above for women on AUDIT-C Alcohol Use Disorders Identification Test
- Pregnant or nursing; AND/OR
- Has a cognitive impairment that would preclude giving consent.
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT01898195
Start Date
March 1 2013
End Date
December 1 2014
Last Update
August 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Spencer Cox Center for Health
New York, New York, United States, 10011